Gene therapy for ovarian cancer (review)
- PMID: 12168087
Gene therapy for ovarian cancer (review)
Abstract
The field of gene therapy presents exciting new opportunities for advances in the management of ovarian cancer. Clinical trials of gene therapy for ovarian cancer have explored the feasibility of delivering a variety of agents as well as highlighted problems with the delivery of therapeutic constructs. Major challenges include enhancing gene transfection with improved vectors, minimizing immunogenicity of viral vectors via novel molecular alterations, effecting tumor-selective gene delivery by targeting genetic alterations present only in tumor cells and utilizing tissue-specific promoters for selective transcription of gene products. Gene therapy research presents unique opportunities for extending the spectrum of ovarian cancer treatment possibilities, either alone or in combination with conventional chemotherapy regimens.
Similar articles
-
The secretory leukoprotease inhibitor (SLPI) promoter for ovarian cancer gene therapy.J Gene Med. 2003 Apr;5(4):300-10. doi: 10.1002/jgm.341. J Gene Med. 2003. PMID: 12692864
-
Delivery of herpes simplex thymidine kinase bystander effect by engineered human mesothelial cells for the treatment of ovarian cancer.Cytotherapy. 2003;5(6):509-22. doi: 10.1080/14653240310003620. Cytotherapy. 2003. PMID: 14660047
-
[In vitro treatment of ovarian cancer cells with cytosine deaminase-thymidine kinase fusion disuicide gene therapy system under the control of human telomerase reverse transcriptase gene promoter].Zhonghua Fu Chan Ke Za Zhi. 2004 Jun;39(6):390-5. Zhonghua Fu Chan Ke Za Zhi. 2004. PMID: 15312323 Chinese.
-
[Gene therapy for ovarian cancer].Nihon Rinsho. 2005 Dec;63 Suppl 12:552-61. Nihon Rinsho. 2005. PMID: 16416852 Review. Japanese. No abstract available.
-
From gene therapy to virotherapy for ovarian cancer.Minerva Ginecol. 2004 Dec;56(6):503-14. Minerva Ginecol. 2004. PMID: 15729203 Review.
Cited by
-
Significance of MNK1 in prognostic prediction and chemotherapy development of epithelial ovarian cancer.Clin Transl Oncol. 2017 Sep;19(9):1107-1116. doi: 10.1007/s12094-017-1646-x. Epub 2017 Mar 22. Clin Transl Oncol. 2017. PMID: 28332091
-
DNA-based therapeutics and DNA delivery systems: a comprehensive review.AAPS J. 2005 Apr 8;7(1):E61-77. doi: 10.1208/aapsj070109. AAPS J. 2005. PMID: 16146351 Free PMC article. Review.
-
DNA as therapeutics; an update.Indian J Pharm Sci. 2009 Sep;71(5):488-98. doi: 10.4103/0250-474X.58169. Indian J Pharm Sci. 2009. PMID: 20502565 Free PMC article.
-
Preparation and characterization of magnetic nanoparticles containing Fe(3)O(4)-dextran-anti-β-human chorionic gonadotropin, a new generation choriocarcinoma-specific gene vector.Int J Nanomedicine. 2011;6:285-94. doi: 10.2147/IJN.S13410. Epub 2011 Feb 2. Int J Nanomedicine. 2011. PMID: 21383853 Free PMC article.
-
Durable expression of minicircle DNA-liposome-delivered androgen receptor cDNA in mice with hepatocellular carcinoma.Biomed Res Int. 2014;2014:156356. doi: 10.1155/2014/156356. Epub 2014 Mar 6. Biomed Res Int. 2014. PMID: 24734226 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical